IGF-1 LR3 injection sites

IGF-1 LR3 is administered subcutaneously in standard rotation across abdomen, thigh, and upper arm. Unlike BPC-157, where local injection near an injury site has a defensible mechanistic rationale, IGF-1 LR3 is a systemic peptide — its 20–30 hour half-life means it equilibrates body-wide regardless of where you inject. The "site-targeted" approach some users try with IGF-1 LR3 (injecting near a working muscle) is largely aspirational, and the standard SubQ rotation is the right default for almost everyone.

Standard injection sites

Standard SubQ technique:

• 30-gauge, 5/16-inch insulin pin (the standard)
• Pinch a fold of skin
• Insert at 45–90 degree angle (depends on adiposity — lean users use 45)
• Inject slowly
• Withdraw, gentle pressure with gauze; don't massage hard

The very small volume (typically 2–4 units) means injection time is essentially instant and discomfort is minimal.

Site rotation

Rotate every injection. The reasons:

• Repeat injection at the same site causes lipohypertrophy (firm, lumpy SubQ tissue) that absorbs unpredictably
• Local irritation accumulates with repetition
• Rotation gives each site 5–7 days minimum to recover

A workable rotation pattern for twice-daily dosing:

This is one defensible pattern; many work. The principle is: don't repeat the same site within 3–4 days.

The peri-muscular site-targeting question

Some users try injecting IGF-1 LR3 near a working muscle (next to chest pre-chest-day, next to back pre-pull-day) on the theory that local concentration will drive a localized hypertrophy response. This is the same theory that drives IGF-1 DES use, but it doesn't transfer cleanly to IGF-1 LR3 for two reasons:

• IGF-1 LR3's long half-life means most of the dose distributes systemically before clearance. The local concentration advantage at the injection site is brief.
• The IGF-1 receptor saturates at relatively low concentrations. Once you've reached saturation systemically, additional local concentration doesn't drive additional signal.

In practice the strongest reported peri-muscular use case (intramuscular IGF-1 near a target muscle pre-workout) is closer to IGF-1 DES territory anyway. For IGF-1 LR3 specifically, standard SubQ rotation captures essentially all of the available benefit.

If you're genuinely committed to local peri-muscular targeting, IGF-1 DES is the molecule designed for it. See IGF-1 LR3 vs IGF-1 DES.

SubQ vs IM for IGF-1 LR3

Subcutaneous is standard. Intramuscular is occasionally used, generally without strong rationale:

Given IGF-1 LR3's long half-life makes peak/trough differences mostly irrelevant, and SubQ is logistically simpler, there's no clear advantage to IM for systemic IGF-1 LR3 dosing. SubQ is the right default.

Technique for very small volumes

The reconstituted IGF-1 LR3 dose is typically 2–4 units on a U-100 insulin syringe. A few practical points:

• Draw extra, then push back. Drawing exactly 2 units cleanly is harder than drawing 4 and pushing 2 back into the vial.
• Tap the syringe to clear air bubbles before injection — even a tiny bubble is meaningful in a 4-unit volume.
• Consider higher BAC water dilution if your draws are too small to be reliable. 1 mg + 2 mL water doubles your draw volume (4 units instead of 2 for a 20 mcg dose). Trade-off is faster reconstituted-peptide degradation. See storage.
• Verify volume before injecting. The cost of a misdose at this scale is real — eyeballing 2 vs 4 units is the difference between 20 mcg and 40 mcg.

What not to do

• Don't inject into scar tissue or stretch marks. Absorption is unpredictable.
• Don't reuse needles. Pin sharpness drops fast; bacterial introduction risk climbs.
• Don't inject through clothing. This sounds obvious but happens.
• Don't massage the site hard post-injection. Gentle pressure only.
• Don't inject at the same site two days running. Lipohypertrophy accumulates faster than people expect.
• Don't try to inject "into" a muscle expecting local effect. The peri-muscular targeting theory doesn't apply to LR3.

Bruising and injection-site reactions

A small, faint bruise at injection sites is normal — IGF-1 LR3 itself isn't particularly irritating, but small superficial veins are easy to nick with the pin. Bruising patterns:

• Tiny dot bruise: common, no concern
• Larger purple bruise: nicked a vein, no concern beyond cosmetic
• Hot, red, swollen, painful: possible infection — stop injecting at that site, monitor; if it spreads or develops fever, see a clinician
• Persistent firm lump: lipohypertrophy from repeat use; rotate away from that site for several weeks

What injection technique can't fix

A few side effects are mechanism-based and don't change with site choice:

• Hypoglycemia is a circulating-IGF-1 effect; inject location doesn't matter
• Hand numbness is systemic; site rotation doesn't help
• Headaches and fatigue in week 1 are systemic adaptation; not site-related

The injection site mostly affects local tolerability and consistency of absorption. The dose response is what it is.

Related reading

• IGF-1 LR3 dosing protocol
• IGF-1 LR3 vs IGF-1 DES
• IGF-1 LR3 storage
• IGF-1 LR3 side effects